Kindstar Global Co.,Ltd announced that it has received funding from Baird Capital Partners Asia, KPCB China, The Mayo Clinic, and WI Harper Group.
January 29, 2012 at 11:00 pm EST
Share
Kindstar Global Co.,Ltd announced that it has raised $20 million in its series C round of funding led by KPCB China Fund, managed by KPCB China on January 30, 2012. The transaction also saw participation from other existing investors WI Harper Group, Baird Capital Partners Asia, and The Mayo Clinic. KPCB China invested $16 million in the transaction. As a part of the round, James Huang of KPCB China will join the company's board of directors. Yijun Chao, Huan Wang and Jiaxin Wu of Han Kun Law Offices served as legal advisors to the company.
On January 30, 2012, Kindstar Global Co.,Ltd closed the transaction.
Kindstar Globalgene Technology Inc is a China-based investment holding company principally engaged in the provision of clinical testing services. The Company operates nine segments. Hematology Testing segment includes testing services related to blood diseases. Genetic Diseases and Rare Diseases segment includes testing services from the rare disease. Infectious Diseases segment includes testing services from the infection department. Oncology segment includes testing related to oncology diseases. Neurology segment includes testing services related to neurological diseases undertaken by the Group. Maternity-related Diseases segment includes testing services related to maternity. COVID-19 Related Testing segment includes testing services related to COVID-19. Routine Testing segment conducts routine tests for the doctorsâ daily diagnoses. The Others segment includes testing services for research and development (R&D) projects and others and miscellaneous services.
KINDSTAR GLOBALGENE TECHNOLOGY, INC. 
